Background: Thrombocytopenia, which is defined as the platelet count below 150000/mm³ or <160×109/L, occurs in 7% pregnancies especially during third trimester of pregnancy. Objective: This study is done to analyze the feto-maternal outcomes of thrombocytopenia at third trimester, in pregnancy. Study Design: This is a prospective observational design study. Duration and Place of the study: This research was conducted at Saidu group of teaching hospital Obs & Gyny Department over a 12-month period, between 12th, April 2021 to 11th, March 2022. Material and Methods: This research included a series of 150 pregnant women with thrombocytopenia diagnosed during the third trimester. Study participants were classified according to severity of thrombocytopenia: mild (100,000- 150,000/mm³), moderate (50,00–99,999mm³) and severe (<50.ooo mm 3). This study also evaluated maternal outcomes in the form of postpartum hemorrhage, platelet transfusion rate, cesarean delivery and preeclampsia. Birth weight, preterm birth, Apgar score and neonatal intensive care unit (NICU) admissions were outcomes for the fetus. Results: A total of 150 peri-partum women with the diagnosis of thrombocytopenia during the third trimester were enrolled in the study. The mean patients’ age was 28.8 ± 3.6 years. A total of 57.3% of all the enrolled women were primigravida. The mean gestational age at the diagnosis was 32.4 ± 1.9 weeks, with no significant differences. ). NICU admissions were significantly increased in the severe cases, compared to that of mild (53.3% vs. 11.4%, p<0.01). Conclusion: The results indicated that more severe thrombocytopenia was significantly associated with an elevated risk for all the adverse outcomes, such as postpartum hemorrhage, platelet transfusion and cesarean delivery.